Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

EVOQ Therapeutics

- PMLiVE

Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

- PMLiVE

Gilead’s New Drug Application for Yeztugo accepted by US FDA

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE

Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance

Wettan has served at Gilead for over 14 years

- PMLiVE

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

- PMLiVE

Gilead agrees on affordable medicines plan with US government

The company recently announced a $32bn investment in US R&D and manufacturing

- PMLiVE

Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

This is the most common type of non-Hodgkin lymphoma worldwide

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links